Highlights
- Anteris Technologies (ASX:AVR) expanded sites for its PARADIGM pivotal trial.
- September-quarter operating cash outflow was USD 22.9 million.
- EMBARK reported 30-day outcomes in 22 medium-annulus patients.
- The DurAVR heart valve remains investigational and unavailable for commercial sale.
Anteris Technologies Global Corp. develops medical devices for structural heart disease, led by its investigational DurAVR transcatheter heart valve system. On 13 November 2026, Anteris Technologies (ASX:AVR) traded at AUD 8.66, down 3.78% during the session. The company's early-November clinical update and third-quarter financial results describe expansion of a pivotal valve study, Manufacturing preparations and spending associated with the development programme.
DurAVR Technology and Treatment Focus
Anteris (ASX:AVR), which is also listed on Nasdaq, is developing DurAVR for patients with severe aortic stenosis, a narrowing of the aortic valve that restricts blood flow. Its device uses a balloon-expandable structure and a single-piece biomimetic valve design intended to resemble the shape of a native valve. The system combines DurAVR, ADAPT anti-calcification tissue and the ComASUR delivery system.
The device is not authorised for commercial sale. Clinical evidence and regulatory review remain necessary before commercial deployment. The company's main development undertaking is the global PARADIGM randomised trial, which compares DurAVR against commercially available transcatheter aortic valve replacements.
Trial Expansion and EMBARK Findings
Anteris stated in its November third-quarter release that PARADIGM was enrolling across active sites in the United States, Canada, Denmark, the Netherlands and France. Following quarter-end, it received German regulatory clearance and made progress in Australia after ethics approval and authorisation through the Therapeutic Goods Administration's Clinical Trial Notification pathway. Regulatory permission to conduct a study does not establish Marketing approval.
The PARADIGM trial is designed to recruit approximately 1,000 participants in its main randomised cohort, allocated equally to DurAVR or an approved comparator. Its primary outcome is a one-year combined measure of mortality, stroke and cardiovascular hospitalisation. The trial is intended to assess non-inferiority against commercially available devices.
Separately, Anteris reported 30-day results in 22 people with medium-sized aortic annuli participating in EMBARK. Mean pressure gradient was 6.17 millimetres of mercury, compared with 45.5 at baseline, while effective orifice area was 2.64 square centimetres versus 0.8 at baseline. The company reported no valve-related deaths and no moderate or severe paravalvular leaks or prosthesis-patient mismatch in this small cohort. These observations require interpretation within the limited study size and follow-up period.
Third-Quarter Financial and Manufacturing Update
Anteris (ASX:AVR) reported net operating cash outflows of USD 22.9 million for the three months to 30 September 2026. Research-and-development expenses were USD 21.3 million, including clinical trial work, site activation, manufacturing-process development and quality-system expansion. This spending reflects activities associated with the pivotal clinical programme rather than sales of an approved DurAVR device.
In September, the company took occupancy of the Northcross Facility in Brooklyn Park, Minnesota. It said the premises would provide capacity for producing DurAVR valves and ComASUR systems as its programme advances. Brent Moen became chief financial officer in September. Operational preparations and expanded infrastructure carry costs before any prospective commercial Revenue is established.
Risks and Near-Term Monitoring Points
A pivotal medical-device trial must meet defined clinical and statistical endpoints, and favourable observations from smaller studies do not guarantee comparable outcomes. Patient enrolment, site activation, manufacturing quality, regulatory requirements and access to Capital can influence timelines and spending. Anteris must also show that manufacturing processes can scale consistently while clinical work proceeds.
The next measurable developments include recruitment across newly authorised jurisdictions, additional DurAVR data, spending disclosures and milestones for the Northcross facility. The planned one-year PARADIGM endpoint means trial execution and follow-up are important before any conclusion about comparative effectiveness.
Key Insights
Anteris (ASX:AVR) is expanding PARADIGM geographically while preparing manufacturing capacity. Its November updates provide early EMBARK observations and quantify substantial research-related expenditure. Larger randomised outcomes, regulatory review and financing requirements remain the decisive items to follow.






Please wait processing your request...